Modality
ERT
MOA
CDK4/6i
Target
SMN2
Pathway
Tau
T2DThymoma
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
Jul 2023
→ Oct 2029
Phase 3Current
NCT07276296
2,536 pts·Thymoma
2023-07→2029-10·Terminated
2,536 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-183.6y awayPh3 Readout· Thymoma
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2029-10-18 · 3.6y away
Thymoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07276296 | Phase 3 | Thymoma | Terminated | 2536 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |